Curr Drug Targets. 2026 Jul 16. doi: 10.2174/0113894501484438260708073917. Online ahead of print.
ABSTRACT
The growing global burden of cardiovascular diseases necessitates the exploration of novel and complementary therapeutic strategies. Hawthorn (Crataegus spp.), a traditional herbal medicine, has gained considerable attention for its potential cardioprotective properties. This review provides a comprehensive overview of the botanical profile, phytochemical composition, and pharmacological activities of hawthorn, highlighting its role as a naturally derived cardiotonic agent. The therapeutic effects of hawthorn are primarily attributed to its bioactive constituents, particularly flavonoids and oligomeric proanthocyanidins, which exhibit vasodilatory, antioxidant, mild positive inotropic, and antiarrhythmic properties. Evidence from preclinical studies and selected clinical investigations suggests that hawthorn may support cardiovascular function, including improvements in exercise tolerance, endothelial function, and symptom management in conditions such as mild-tomoderate heart failure, hypertension, and angina. However, it is important to note that the current evidence is largely derived from secondary sources, including preclinical data and limited clinical trials, and does not establish hawthorn as a curative or standalone therapy. Compared with synthetic cardiotonic agents, hawthorn demonstrates a favorable safety profile, though variability in extract composition and dosing remains a significant limitation. Overall, while hawthorn shows promise as an adjunctive therapy in cardiovascular disease management, further well-designed, large-scale clinical studies and standardized formulations are required to validate its efficacy, clarify mechanisms of action, and support its integration into evidence-based clinical practice.
PMID:42473213 | DOI:10.2174/0113894501484438260708073917